Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])

The messenger RNA vaccine against SARS-CoV-2 is effective at preventing COVID-19-associated hospitalization, and the Centers for Disease Control and Prevention has recommended vaccination for all eligible individuals. We demonstrate a case involving a patient who developed a life-threatening acute a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Masaru, Satonaga, Yoshio, Takaki, Ryuichiro, Yabe, Michitoshi, Kan, Takamasa, Omote, Erika, Yamasaki, Toru, Komiya, Kosaku, Hiramatsu, Kazufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477784/
https://www.ncbi.nlm.nih.gov/pubmed/36122668
http://dx.doi.org/10.1016/j.ijid.2022.09.019
_version_ 1784790438575603712
author Ando, Masaru
Satonaga, Yoshio
Takaki, Ryuichiro
Yabe, Michitoshi
Kan, Takamasa
Omote, Erika
Yamasaki, Toru
Komiya, Kosaku
Hiramatsu, Kazufumi
author_facet Ando, Masaru
Satonaga, Yoshio
Takaki, Ryuichiro
Yabe, Michitoshi
Kan, Takamasa
Omote, Erika
Yamasaki, Toru
Komiya, Kosaku
Hiramatsu, Kazufumi
author_sort Ando, Masaru
collection PubMed
description The messenger RNA vaccine against SARS-CoV-2 is effective at preventing COVID-19-associated hospitalization, and the Centers for Disease Control and Prevention has recommended vaccination for all eligible individuals. We demonstrate a case involving a patient who developed a life-threatening acute asthma exacerbation after receiving their third dose of the BNT16b2 vaccine. Because eosinophilia was observed after the second inoculation, it was considered likely that the patient had been sensitized to the BNT16b2 vaccine. Theoretically, the SARS-CoV-2 vaccine could trigger the exacerbation of asthma. It should be recognized that repeated SARS-CoV-2 vaccination may be a risk factor for the acute exacerbation of asthma.
format Online
Article
Text
id pubmed-9477784
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-94777842022-09-16 Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)]) Ando, Masaru Satonaga, Yoshio Takaki, Ryuichiro Yabe, Michitoshi Kan, Takamasa Omote, Erika Yamasaki, Toru Komiya, Kosaku Hiramatsu, Kazufumi Int J Infect Dis Case Report The messenger RNA vaccine against SARS-CoV-2 is effective at preventing COVID-19-associated hospitalization, and the Centers for Disease Control and Prevention has recommended vaccination for all eligible individuals. We demonstrate a case involving a patient who developed a life-threatening acute asthma exacerbation after receiving their third dose of the BNT16b2 vaccine. Because eosinophilia was observed after the second inoculation, it was considered likely that the patient had been sensitized to the BNT16b2 vaccine. Theoretically, the SARS-CoV-2 vaccine could trigger the exacerbation of asthma. It should be recognized that repeated SARS-CoV-2 vaccination may be a risk factor for the acute exacerbation of asthma. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-11 2022-09-16 /pmc/articles/PMC9477784/ /pubmed/36122668 http://dx.doi.org/10.1016/j.ijid.2022.09.019 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Ando, Masaru
Satonaga, Yoshio
Takaki, Ryuichiro
Yabe, Michitoshi
Kan, Takamasa
Omote, Erika
Yamasaki, Toru
Komiya, Kosaku
Hiramatsu, Kazufumi
Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])
title Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])
title_full Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])
title_fullStr Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])
title_full_unstemmed Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])
title_short Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])
title_sort acute asthma exacerbation due to the sars-cov-2 vaccine (pfizer-biontech bnt162b2 messenger rna covid-19 vaccine [comirnaty(ⓡ)])
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477784/
https://www.ncbi.nlm.nih.gov/pubmed/36122668
http://dx.doi.org/10.1016/j.ijid.2022.09.019
work_keys_str_mv AT andomasaru acuteasthmaexacerbationduetothesarscov2vaccinepfizerbiontechbnt162b2messengerrnacovid19vaccinecomirnaty
AT satonagayoshio acuteasthmaexacerbationduetothesarscov2vaccinepfizerbiontechbnt162b2messengerrnacovid19vaccinecomirnaty
AT takakiryuichiro acuteasthmaexacerbationduetothesarscov2vaccinepfizerbiontechbnt162b2messengerrnacovid19vaccinecomirnaty
AT yabemichitoshi acuteasthmaexacerbationduetothesarscov2vaccinepfizerbiontechbnt162b2messengerrnacovid19vaccinecomirnaty
AT kantakamasa acuteasthmaexacerbationduetothesarscov2vaccinepfizerbiontechbnt162b2messengerrnacovid19vaccinecomirnaty
AT omoteerika acuteasthmaexacerbationduetothesarscov2vaccinepfizerbiontechbnt162b2messengerrnacovid19vaccinecomirnaty
AT yamasakitoru acuteasthmaexacerbationduetothesarscov2vaccinepfizerbiontechbnt162b2messengerrnacovid19vaccinecomirnaty
AT komiyakosaku acuteasthmaexacerbationduetothesarscov2vaccinepfizerbiontechbnt162b2messengerrnacovid19vaccinecomirnaty
AT hiramatsukazufumi acuteasthmaexacerbationduetothesarscov2vaccinepfizerbiontechbnt162b2messengerrnacovid19vaccinecomirnaty

Ejemplares similares